You just read:

Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA

News provided by

Valeant Pharmaceuticals International, Inc.

Aug 07, 2017, 16:17 ET